Nisoxetine|CAS 53179-07-0|DC Chemicals

Cas No.:	53179-07-0
Chemical Name:	Benzenepropanamine, g-(2-methoxyphenoxy)-N-methyl-
Synonyms:	Benzenepropanamine, g-(2-methoxyphenoxy)-N-methyl-;3-(2-Methoxyphenoxy)-N-methyl-3-phenyl-1-propanamine;[3H]-Nifedipine;[3H]-Nisoxetine;1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester;4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine;4-(2-nitrophenyl)-3,5-dimethoxycarbonyl-2,6-dimethyl-1,4-dihydropyridine;Adalat;Corinfar;Fenihidin;Fenihidine;nifedipine;N-methyl-3-(2-methoxyphenoxy)-3-phenyl-1-propylamine;N-methyl-3-(2-methoxyphenoxy)-3-phenylpropylamine;Procardia;Nisoxetine;3-(2-Methoxyphenoxy)-N-methyl-3-phenylpropylamine;ANTIOXIDANT1425;Compound 89218;SPBio_002959;BDBM22417;Prestwick3_000910;AS-16468;N-methyl 3-(o-methoxyphenoxy)-3-phenylpropylamine;Nisoxetine Inhibitor;BRD-A95696066-003-03-9;CHEBI:73410;Compound 89218; NSC 283481;LY 94939;CCG-204983;NISOXETINE [INN];CHEMBL295467;BRD-A95696066-003-06-2;Nisoxetina;UNII-17NV064B2D;NSC 283481;NCGC00015715-08;57226-61-6;NISOXETINE [USAN];NCGC00015715-04;DTXCID8025175;GTPL4637;DL-N-Methyl-3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine;BENZENEPROPANAMINE, .GAMMA.-(2-METHOXYPHENOXY)-N-METHYL-, (+/-)-;DTXSID0045175;CAS-53179-07-0;Nisoxetine (USAN/INN);Tox21 110203;Tox21_110203;DB09186;NCGC00015715-03;NCGC00015715-15;17NV064B2D;NSC283481;D05173;Q906885;53179-07-0;Nisoxetine [USAN:INN];Prestwick2_000910;AB00514644-07;LY-94939;NSC-283481;Prestwick0_000910;NCGC00015715-06;N-Methyl-gamma-(2-methylphenoxy)phenylpropanolamine;AB00514644;3-(o-Methoxyphenoxy)-N-methyl-3-phenylpropylamine;PDSP2_000505;HMS2089K13;BPBio1_000836;Lopac0_000901;COMPOUND-89218;NCGC00024945-02;NCGC00024945-03;[3-(2-methoxyphenoxy)-3-phenylpropyl](methyl)amine;(+/-)-3-(O-METHOXYPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE;3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine;BSPBio_000760;Tox21_110203_1;NCGC00015715-05;Benzenepropanamine, gamma-(2-methoxyphenoxy)-N-methyl-;Nisoxetinum;SCHEMBL124289;SDCCGSBI-0050876.P002;NS00002148;N-methyl-3-phenyl-3-(o-methoxyphenoxy)-propylamine;PDSP1_000507;N-methyl 3(o-methoxyphenoxy)-3-phenylpropylamine;Prestwick1_000910;DA-56190;BRD-A95696066-003-13-8;EX-A9581
SMILES:	CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC
Formula:	C₁₇H₂₁NO₂
M.Wt:	271.35414
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.